Fluidigm launches new Biomark X microfluidics platform
The new microfluidics platform, Biomark X, has a broad menu of applications and promises to streamline operations to reduce hands-on time
The new microfluidics platform, Biomark X, has a broad menu of applications and promises to streamline operations to reduce hands-on time
A new platform to simplify deep profiling of the human immune system
Collaboration agreement to market AZOVA COVID-19 test collection kit online
The testing capacity provided by the Fluidigm system aims to help the university limit the spread of the virus
The extraction-free saliva-based test detects nucleic acid from the SARS-CoV-2 virus
Fluidigm COVID-19 campus safeguard program improves availability of non-invasive, saliva-based SARS-CoV-2 tests for higher education institutions
The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays
The test is intended to expand availability of COVID-19 screening resources in central Ohio
Providing researchers with expanded capabilities in interrogating the tissue microenvironment
Study suggests that type I IFN deficiency in the blood could help define a high-risk population
Take an interactive tour of the Hyperion Imaging System and meet experts in imaging mass cytometry at the Fluidigm booth 3420
histoCAT software to enable deep interrogation of tissues with multiplex imaging mass cytometry
Advanta qPCR assay to enable advanced tumor immunobiology analysis
7 UK universities to acquire Helios mass cytometry systems to drive life-changing health discoveries